Trial Profile

A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ontamalimab (Primary)
Indications Crohn's disease; Ulcerative colitis
Focus Adverse reactions; Pharmacodynamics
Acronyms AIDA
Sponsors Shire; Shire Human Genetic Therapies; Takeda

Most Recent Events

14 Feb 2024 This trial has been completed in Hungary ,Ireland, Belgium according to European Clinical Trials Database record.
08 Feb 2024 This trial has been completed in poland, according to European Clinical Trials Database record.
06 Feb 2024 This trial has been completed in Bulgaria , according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com